Lowered costs and incremental effectiveness could improve when using biomarker-guided selection for treatment of patients with metastatic colorectal cancer using first-line nivolumab. Choosing the ...
This cost-utility analysis compares the cost-effectiveness of salmeterol, fluticasone propionate, combination salmeterolfluticasone, and no maintenance therapy in chronic obstructive pulmonary disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback